This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Saffron
Crocus sativus stigma extract | "the red gold" | crocins + crocetins + safranal
Aliases (6)
Overview
What is Saffron?
Saffron is the dried stigma of Crocus sativus, the world's most expensive spice and a centuries-old folk remedy for low mood and PMS. The standardized supplement form (affron from Pharmactive, Satiereal from INOREAL) concentrates the bioactive carotenoids (crocins, crocetin) and the volatile aldehyde safranal that drive its mood and cognitive effects. GRAS food + OTC supplement; not WADA-banned.
Key Benefits
SSRI-comparable signal in mild-to-moderate depression at 28-30 mg/day, modest anxiety and PMS symptom reduction, MCI/Alzheimer benefit at extended dosing, and adjunct utility for SSRI-induced sexual dysfunction. Generally well-tolerated; not a replacement for prescribed antidepressants in clinical depression.
Mechanism of Action
Multi-target botanical: serotonergic modulation (crocins inhibit serotonin reuptake in animal models — paroxetine-like signal but weaker), GABAergic potentiation (safranal modulates GABA-A), antioxidant + anti-inflammatory effects via crocetin, and weak NMDA modulation. No single primary receptor; the mood effect is the headline indication.
Pharmacokinetics
Peptide Interactions
Different mechanism (rhodiola = MAO + monoamine reuptake nudge + adaptogenic HPA modulation; saffron = SSRI-like + GABAergic + antioxidant). Logical AM/PM sp…
Complementary — ashwagandha = cortisol attenuation via HPA-axis modulation; saffron = direct mood/serotonergic. Strong pairing for combined stress-plus-mood …
Both modulate GABAergic tone with non-overlapping mechanisms (theanine = AMPA antagonism + glutamate transporter modulation; safranal = GABA-A allosteric). C…
Cognitive and sleep complementarity via NMDA modulation. Already in V4.
Theoretical complement — 5-HTP raises serotonin substrate availability, saffron may slow reuptake/breakdown. Caution: stack with vigilance for serotonin synd…
Theoretical additive serotonergic effect. Most trials run saffron as monotherapy or as SSRI alternative. Use only with clinician oversight. The Lopresti 2019…
Saffron has weak in-vitro MAO-A/B inhibition. Combining with prescription non-selective MAOIs carries theoretical hypertensive crisis / serotonin syndrome ri…
Likely OK; no reports of issue. At >10 mg/day selegiline loses MAO-B selectivity — increases concern.
Both serotonergic; additive risk. Avoid co-administration.
All have serotonergic components — theoretical interaction at higher saffron doses.
Mild antiplatelet effect; caution at supratherapeutic saffron doses or therapeutic anticoagulation.
Quality Indicators
Standardized extract (affron or Satiereal)
Trial-replicating products use Pharmactive's affron (3.5% Lepticrosalides) or INOREAL's Satiereal. These match the standardization used in published RCTs and provide consistent crocin/safranal content.
Third-party COA + ISO 3632 grading
ISO 3632 is the international saffron quality standard. Category I saffron has the highest crocin (color), picrocrocin (taste), and safranal (aroma) values. Reputable supplements publish grade or COA.
Generic 'saffron extract' without standardization
Unstandardized capsules vary 5x+ in crocin/safranal content. Trial findings may not transfer. Without affron / Satiereal / equivalent standardization, dose-response is unpredictable.
Adulteration with safflower / turmeric / marigold
Saffron is the world's most expensive spice and is heavily adulterated. Cheap 'saffron' supplements are often dyed safflower (Carthamus tinctorius), turmeric, or marigold petals — none of which contain the active crocins/safranal. Suspiciously cheap product = adulteration risk.
Megadose claims (>200 mg/day)
Therapeutic dose is 28-30 mg/day standardized extract. Doses above 1.5 g/day raise toxicity concerns (vomiting, mucosal bleeding). Products marketing megadoses are either unstandardized (so 'mg' is meaningless) or unsafe.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Common (>10%): Generally none of clinical significance at 28-30 mg/day. Rare mild GI upset, headache, mild drowsiness.
- Less common (1-10%): Reduced appetite (transient), nausea (usually transient), paradoxical mild anxiety (rare, first week).
- **Rare-serious (<1%):** **No serious adverse events documented at standard 28-30 mg/day** across the trial literature. Very high doses (>1.5 g/day) raise concerns; >5 g/day historically used as abortifacient with case reports of thrombocytopenia, severe GI symptoms, vertigo, and hematological derangement. The therapeutic window above 30 mg/day is functionally unmapped.
- Theoretical:
- Serotonin syndrome risk if combined with SSRIs/SNRIs/MAOIs at full clinical doses — theoretical and not documented at 30 mg/day supplement dosing, but the in-vitro MAO-A inhibition is real enough that the caution stands.
- Mild antiplatelet effect at higher doses — caution with warfarin, DOACs, aspirin, or pre-surgery contexts at supratherapeutic dosing.
- Yellow skin / sclera discoloration — rare, with chronic very-high-dose use due to crocin pigment deposition. Reversible. Functionally a non-issue at 30 mg/day.
- Uterotonic effect at high doses → CONTRAINDICATED IN PREGNANCY.
- Specific watch periods:
- First 2 weeks for GI tolerance
- Week 4-6 for mood evaluation (insufficient response is the most common reason for discontinuation)
- Long-term beyond 12 weeks — limited published data; presumed safe at 28-30 mg/day given GRAS status
NOT a replacement for prescribed antidepressants in clinical depression. For diagnosed MDD, saffron is at best an adjunct or a step-down option after clinical stabilization — not a first-line substitute for SSRI therapy where clinically indicated. The non-inferiority signal is real in trial populations but Iranian RCT cohorts may not be fully transferable, and individual treatment effects vary widely.
Athlete-specific notes (relevant to this user, MMA training context): No ergogenic effect. No WADA banned-substance status (not on the Prohibited List 2026). Mild antiplatelet effect at higher doses could theoretically extend bruising / contact-sport hematoma resolution, but this is a stretch at 30 mg/day. No reported impact on testosterone, LH, FSH, or anabolic markers. No interaction with creatine, beta-alanine, or standard training stack.
References
Lopresti & Drummond 2014 — Saffron systematic review (Hum Psychopharmacol)
Hausenblas et al. 2013 — Saffron MDD meta-analysis (J Integr Med)
Noorbala et al. 2005 — Saffron vs fluoxetine head-to-head (J Ethnopharmacol)
Akhondzadeh et al. 2010 — Saffron vs donepezil in mild-moderate AD (Psychopharmacology)
Akhondzadeh et al. 2010 — Saffron vs placebo in mild-moderate AD (J Clin Pharm Ther)
Modabbernia et al. 2012 — Saffron for fluoxetine-induced sexual dysfunction in men (Psychopharmacology)
Kashani et al. 2013 — Saffron for fluoxetine-induced sexual dysfunction in women (Hum Psychopharmacol)
Kell et al. 2017 — affron in adults with self-reported low mood (Complement Ther Med)
Lopresti et al. 2018 — affron in youth anxiety/depression (J Affect Disord)
Lopresti et al. 2020 — affron for sleep quality (J Clin Sleep Med)
Baziar et al. 2019 — Saffron vs methylphenidate in pediatric ADHD (J Child Adolesc Psychopharmacol)
Falsini et al. 2010 — Saffron for early AMD retinal flicker sensitivity (Invest Ophthalmol Vis Sci)
Umigai et al. 2011 — Crocetin pharmacokinetics in healthy adults (Phytomedicine)
Sabatino et al. 2011 — HPLC/PDA/ESI-MS saffron adulteration detection (Nat Prod Commun)
Shafiee et al. 2018 — Saffron in depression, anxiety, and other mental disorders review (J Affect Disord)
Latest research
- rctCrocus sativus L. vs methylphenidate in pediatric ADHD — RCT (J Child Adolesc Psychopharmacol)Baziar et al. — n=54 children 6-17 with DSM-5 ADHD, 6 weeks saffron 20-30 mg/day (weight-adjusted) vs methylphenidate 20-30 mg/day. No significant difference between groups on Teacher/Parent ADHD Rating Scales. Pilot signal for saffron-MPH equivalence in pediatric ADHD; replication and adult data still needed.
- meta-analysisThe Efficacy of Saffron in the Treatment of Mild to Moderate Depression — meta-analysis (Planta Med)Tóth et al. — 11 RCTs qualitatively assessed, 9 pooled (n>500). Saffron significantly outperformed placebo (Hedges g=0.891, 95% CI 0.369-1.412, p=0.001) and was non-inferior to tested antidepressants (fluoxetine, imipramine, citalopram). Largest, most-rigorous saffron-depression meta to date.
- systematic-reviewSaffron (Crocus sativus) for depression — systematic review (Hum Psychopharmacol)Lopresti & Drummond — 6 clinical studies reviewed; saffron showed large effect sizes vs placebo and equivalence vs antidepressant medication. Foundational mechanism-and-clinical synthesis.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.